Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues.

Ther Adv Gastroenterol · 2021 · PMC8669878 · PMID 34917173

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

100 Recent data from the phase III SERENE maintenance study in UC demonstrated a trend towards improved outcomes with an intensive adalimumab maintenance regimen (40 mg every week [EW]), compared with standard dosing (40 mg every other week [EOW]); however, this did not reach statistical significance after 8 weeks of maintenance treatment (in addition to the 8-week induction phase).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.